EUROPEAN PARLIAMENT

2004 **** 2009

Committee on the Environment, Public Health and Food Safety

16.2.2006 PE 370.102v01-00

AMENDMENTS 1-4

Draft opinion (PE 362.659v01-00) Satu Hassi

Proposal for a decision of the European Parliament and the Council concerning the seventh framework programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Proposal for a decision (COM(2005)0119 - C6-0099/2005 - 2005/0043(COD))

Text proposed by the Commission

Amendments by Parliament

Compromise amendment 1 by Satu Hassi, on behalf of the GREENS/ALE Group; Dimitrios Papadimoulis, on behalf of the GUE/NGL Group

(Compromise amendment to be voted together with AM 39)
Recital 17

(17) The seventh Framework Programme complements the activities carried out in the Member States as well as other Community actions that are necessary for the overall strategic effort for the implementation of the Lisbon objectives, alongside in particular those on structural funds, agriculture, education, training, competitiveness and innovation, industry, employment and environment.

(17) The seventh Framework Programme complements the activities carried out in the Member States as well as other Community actions that are necessary for the overall strategic effort for the implementation of the Lisbon objectives, alongside in particular those on structural funds, agriculture, education, training, competitiveness and innovation, industry, employment and environment. Any EU funding for clean coal research should be conducted through the Research Fund for Coal and Steel (RFCS).

AM\602660EN.doc PE 370.102v01-00

EN EN

Justification

At the time that FP6 started, the Treaty establishing the European Coal and Steel Community expired, leaving behind assets of \in 435 million for Europe's coal industry. The Commission manages the interest from this reserve to provide annual funding equivalent to approximately \in 16 million to coal-related research through the Research Fund for Coal and Steel. These resources are sufficient to cover any EU co-funding if it were considered necessary.

Compromise amendment 2 by Cristina Gutiérrez-Cortines, on behalf of the EPP-ED Group; Frédérique Ries, on behalf of the ALDE Group; Satu Hassi, on behalf of the GREENS/ALE Group; Dimitrios Papadimoulis, on behalf of the GUE/NGL Group

(Compromise amendment replacing Amendment 12, 97, 98, 99, 100, 101) Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Objective"

Improving the health of European citizens and *increasing the competitiveness* of European *health-related industries and businesses*, while addressing global health issues including emerging epidemics. Emphasis will be put on translational research (translation of basic discoveries in *clinical* applications), the development and validation of new therapies, methods for health promotion and prevention, diagnostic tools and technologies, as well as sustainable and efficient healthcare systems.

Improving the *physical and mental* health of European citizens and contributing to the performance of the European health sector. while supporting the competitiveness of businesses related to that sector and addressing global health issues including emerging epidemics, orphan diseases and neglected diseases. Research will aim both at the prevention of diseases and the development of effective treatments and medicines while ensuring equitable access to results of publicly funded research. Emphasis will be put on translational research (translation of basic discoveries in applications at clinical and population *level*), the development and validation of new therapies, methods for health promotion and prevention, diagnostic tools and technologies, technologies for healthy ageing as well as sustainable, accessible and efficient healthcare systems.

Or. en

Compromise amendment 3 by Satu Hassi, on behalf of the GREENS/ALE Group; Dimitrios Papadimoulis, on behalf of the GUE/NGL Group

(Compromise amendment replacing Amendment 14, to be voted together with AM 160) Annex I, Part I, Section "Themes", Point 1 "Health", Subpoint "Rationale", paragraph 3

A strong EU-based biomedical research will help strengthen the competitiveness of the European healthcare biotechnology, medical technology and pharmaceutical industries. The EU also has to play an active role in creating an environment conducive to innovation in the pharmaceutical sector, in particular to maximise the success of clinical research. Research-based SMEs are the main economic drivers of the healthcare biotechnology and medical technology industries. Although Europe now has more Biotechnology companies than US, most of them are small and less mature than their competitors. Public-private research efforts at the EU level will facilitate their development. EU research will also contribute to the development of new norms and standards to set up an appropriate legislative framework for new medical technologies (e.g. regenerative medicine).

A strong EU-based biomedical research will help strengthen the competitiveness of the European healthcare biotechnology, medical technology and pharmaceutical industries. Research-based SMEs are the main economic drivers of the healthcare biotechnology and medical technology industries. Although Europe now has more Biotechnology companies than the US, most of them are small and less mature than their competitors. Public-private research efforts at the EU level will facilitate their development. EU research will also contribute to the development of new norms and standards to set up an appropriate legislative framework for new medical technologies (e.g. regenerative medicine). EU research funding will give priority to adult stem cell and umbilical cord stem cell research and other alternatives to embryonic stem cell research.

Or. en

Compromise amendment 4 by Cristina Gutiérrez-Cortines, on behalf of the EPP-ED Group; Frédérique Ries, on behalf of the ALDE Group; Satu Hassi, on behalf of the GREENS/ALE Group; Dimitrios Papadimoulis, on behalf of the GUE/NGL Group

(Compromise amendment replacing Amendment 129, 130)
Annex I, Part I, Section "Themes", Point 6 "Environment (including Climate Change),
Subpoint "Activities", subheading "Climate change, pollution and risks", indent 1

- Pressures on environment and climate: Functioning of climate and the earth system; adaptation and mitigation measures; pollution in air, soil and water; changes in atmospheric composition and water cycle; interactions between climate, land surface and the ocean; and impacts on biodiversity
- Pressures on environment and climate, including causes of climate change and previous changes ('palaeoclimate'):
 Functioning of climate and the earth system; adaptation and mitigation measures; pollution in air, soil and water; changes in atmospheric composition and water cycle;

and ecosystems.

interactions between climate, land surface and the ocean; *interaction between agriculture and climate change* and impacts on biodiversity and ecosystems.

Or. en